PMEL
ENSG00000185664
Target class
Unclassified protein
Chromosome
12
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- PMEL
- Gene name
- Premelanosome protein
- Gene symbol
- PMEL
- Protein name
- Melanocyte protein PMEL (ME20-M) (ME20M) (Melanocyte protein Pmel 17) (Melanocytes lineage-specific antigen GP100) (Melanoma-associated ME20 antigen) (P1) (P100) (Premelanosome protein) (Silver locus protein homolog) [Cleaved into: M-alpha (95 kDa melanocyte-specific secreted glycoprotein) (P26) (Secreted melanoma-associated ME20 antigen) (ME20-S) (ME20S); M-beta]
- D12S53E
- SI
- Pmel17
- gp100
- HMB-45
- ME20
- HMB45
- SIL
- SILV
- Gene biotype
- Protein coding
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 23
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 38.15
- Tissue specificity (Gini)
- 0.759
- Tissue specificity (tau)
- 0.953
- KEGG gene identifiers
- hsa:6490
- Reactome pathways
- R-HSA-9824585
- Protein interaction confidence
- 0.840188
- Protein interaction partners
- 16
- End position
- 55973317
- Start position
- 55954104
- Chromosome
- 12
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Single-pass type I membrane protein . Golgi apparatus, cis-Golgi network membrane
- Single-pass type I membrane protein . Endosome, multivesicular body . Melanosome . Extracellular vesicle . Secreted . Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065). Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes (PubMed:11694580, PubMed:12643545). Sorted to stage I melanosomes following its processing in the ER and cis-Golgi (PubMed:15096515). Transiently expressed at the cell surface before targeting to early melanosomes (PubMed:16760433, PubMed:30988362). Colocalizes with BACE2 in stage I and II melanosomes (PubMed:23754390). Colocalizes with CD63 and APOE at exosomes and in intraluminal vesicles within multivesicular endosomes (PubMed:21962903, PubMed:26387950). .
- Endoplasmic reticulum
- Golgi apparatus
- PubMed 15096515
- PubMed 15695812
- PubMed 19047044
- PubMed 11694580
- PubMed 17991747
- PubMed 21962903
- PubMed 26387950
- PubMed 12643545
- PubMed 17081065
- PubMed 23754390
- PubMed 8179825
- PubMed 16760433
- PubMed 30988362
- Tissue specificity (tau)
- 0.953204
- Expression inequality (Gini)
- 0.75934
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 38.15
- Skin - Not Sun Exposed (Suprapubic)
- 36.44
- Testis
- 7.58
- Cervix - Ectocervix
- 7.05
- Ovary
- 3.32
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)38.15
- Skin - Not Sun Exposed (Suprapubic)36.44
- Testis7.58
- Cervix - Ectocervix7.05
- Ovary3.32
- Uterus2.69
- Breast - Mammary Tissue2.53
- Cervix - Endocervix2.18
- Liver1.88
- Minor Salivary Gland1.79
- Small Intestine - Terminal Ileum1.73
- Fallopian Tube1.65
- Thyroid1.61
- Cells - EBV-transformed lymphocytes1.55
- Vagina1.51
- Kidney - Medulla1.37
- Colon - Transverse1.2
- Pancreas1.18
- Prostate1.16
- Adipose - Visceral (Omentum)1.1
- Artery - Aorta1.1
- Lung1.02
- Stomach1.01
- Kidney - Cortex0.92
- Adipose - Subcutaneous0.84
And 29 more, listed on the interactive page.
Biological processes
- GO:0032438
- GO:0005576
- GO:0005783
- GO:0005789
- GO:0005794
- GO:0005886
- GO:0032585
- GO:0033106
- GO:0033162
- GO:0042470
- GO:0070062
- GO:0097487
- GO:1903561
- GO:0005515
- GO:0042802
Related records
Trials (19)
- A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
- A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
- A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
- Adjuvant Tebentafusp in High Risk Ocular Melanoma
- DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
- IMCgp100 in Advanced Unresectable Melanoma
- IMCgp100-401 Rollover Study
- Neoadjuvant Tebentafusp for Uveal Melanoma
- Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
- Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
- Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Tebentafusp-tebn With LDT in Metastatic UM
Drugs (1)
- Tebentafusp Melanocyte protein PMEL binding agent